Working with a user aligned model for creative work is a magical feeling.

Dario has written that we need to “pace the frontier,” and Sam has agreed. People may be surprised by my response: go ahead. You guys are the frontier. By any reasonable metric — market share, revenue growth, model capability — the two of you have a duopoly on frontier intelligence. You’ve also claimed the lead is widening because of recursive self-improvement. I don’t see what you see in the lab. If the unreleased models are scary enough that you think you should slow down, I support your decision to be responsible. But stop pretending you need anyone else’s permission. Stop pretending antitrust law has to be suspended so you can form a cartel. Stop pretending you need a regulatory approval process that supersedes product liability. Stop pretending METR is independent when it is intertwined with Anthropic’s investors and staff. Stop pretending you need those same evaluators to police competitors who aren’t even at the frontier. Most of all, stop pretending the motivation to slow down is purely altruistic. You face massive product-liability exposure if your products enable a truly damaging cyberattack. The market already punishes models that behave in unpredictable or unauthorized ways. After the Hugging Face episode, it is simply good business for OpenAI and Anthropic to trade some raw power for reliability and predictability. Call it alignment if you want. It is also just giving customers what they want. Pacing the frontier would also create breathing room for a more intelligent conversation about regulation than Bernie Sanders’ “shut it all down.” China is very unlikely to join a global agreement, as you know, and that has to be taken into account as well. So go ahead and pace the frontier. You are the ones setting it. The easiest way not to build superintelligence is for you to agree not to build it. Demanding your preferred regulatory framework as the price of that will look like blackmail of the public and the political system. So just do it. If you do, you’ll buy goodwill for the next conversation. If you don’t, we’ll know this was just another bid for regulatory capture — or an election-season psyop.

Congratulations to @AAlphaBio on launching the Atlas Consortium! We’re proud to support this work as a founding member alongside @GSK, @Boltz, and @Cradle. Large-scale, standardized experimental data is an invaluable resource for AI drug discovery, and this is a first-of-its-kind framework for generating it at scale and sharing it across a consortium. Connecting AI with real-world experimentation is central to our work at Dyno, as is building and contributing to collaborative resources that move the entire field toward safe, effective, accessible medicines, giving patients everywhere greater agency over their health.

Boston’s first ever @Techweek_ kicks off today and we’re proud to be a founding host! This Thursday, catch Dyno CEO @ekelsic on a panel with @JorgeCondeBio of @a16z and Katherine Andersen of @HSBCInnovation to discuss how AI is delivering real impact in healthcare now, and what comes next. For Dyno, that future is centered on giving patients everywhere the ability to improve their health by taking action at the genetic level through safe, effective, and accessible genetic medicines – that’s what our vision of #GeneticAgency is all about. 📍 Next in Care: How AI is Reshaping Healthcare Hosted by HSBC Innovation Banking and a16z Thursday, May 28 | 4–6 p.m. | Boston, MA Learn more: partiful.com/e/hTsMJ9EKZar9x…